Clinical Trials Logo

Clinical Trial Summary

End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.


Clinical Trial Description

AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02704065
Study type Observational
Source Istanbul University
Contact
Status Completed
Phase N/A
Start date February 2016
Completion date December 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06397001 - Treatment of AA Amyloidosis Phase 1
Not yet recruiting NCT06354322 - Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis